Togo Yamada

Mr. Togo Yamada

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2026 in Fermentation
Verified
Journal Article
Open access
PDF file
TYTogo Yamada
Togo Yamada
Pamella AprilianaPamella Apriliana
Pamella Apriliana
Prihardi KaharPrihardi Kahar
Prihardi Kahar
TKTomoya Kobayashi
Tomoya Kobayashi
YMYutaro Mori
Yutaro Mori
Chiaki OginoChiaki Ogino
Chiaki Ogino
3-Amino-4-hydroxybenzoic acid (3,4-AHBA) is a non-proteinogenic aromatic compound that functions as a key biosynthetic precursor for diverse secondary metabolites with pharmaceutical and industrial value. Microbial production of 3,4-AHBA offers a sustainable alternative to petroleum-based chemical synthesis; however, metabolic complexity and trade-offs between growth and product formation constrain rational strain design. Here, genome-scale metabolic (GSM) modeling and flux balance analysis (FBA) were integrated with targeted genetic engineering to elucidate and enhance 3,4-AHBA production in Streptomyces thermoviolaceus. A genome-scale metabolic model was constructed and expanded by incorporating the nspH–nspI gene operon, which encodes the 3,4-AHBA biosynthetic pathway. In silico FBA predicted substantial rewiring of central carbon metabolism, with carbon flux redirected from glycolysis and the tricarboxylic acid cycle toward aspartate-derived intermediates and 3,4-AHBA synthesis, accompanied by reduced biomass-associated flux. Guided by these predictions, an engineered strain (St::NspHI) was developed and experimentally evaluated. Consistent with model predictions, the engineered strain exhibited lower growth rates and glucose uptake than the wild type, reflecting a metabolic burden. Nevertheless, 3,4-AHBA production was achieved exclusively in the engineered strain. Comparison of simulated and experimental fluxes revealed overestimation by FBA, likely due to secondary metabolism and incomplete genome annotation. Overall, GSM-guided design enables optimization of precursor production.

6 January 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
TYTogo Yamada
Togo Yamada
Pamella AprilianaPamella Apriliana
Pamella Apriliana
Prihardi KaharPrihardi Kahar
Prihardi Kahar
TKTomoya Kobayashi
Tomoya Kobayashi
YMYutaro Mori
Yutaro Mori
Chiaki OginoChiaki Ogino
Chiaki Ogino
3-Amino-4-hydroxybenzoic acid (3,4-AHBA) is a non-proteinogenic aromatic compound that functions as a key biosynthetic precursor for diverse secondary metabolites with pharmaceutical and industrial value. Microbial production of 3,4-AHBA offers a sustain-able alternative to petroleum-based chemical synthesis; however, metabolic complexity and trade-offs between growth and product formation constrain rational strain design. Here, genome-scale metabolic (GSM) modeling and flux balance analysis (FBA) were in-tegrated with targeted genetic engineering to elucidate and enhance 3,4-AHBA production in Streptomyces thermoviolaceus. A genome-scale metabolic model was constructed and ex-panded by incorporating the nspH–nspI gene operon, which encodes the 3,4-AHBA bio-synthetic pathway. In silico FBA predicted substantial rewiring of central carbon metabo-lism, with carbon flux redirected from glycolysis and the tricarboxylic acid cycle toward aspartate-derived intermediates and 3,4-AHBA synthesis, accompanied by reduced bio-mass-associated flux. Guided by these predictions, an engineered strain (St::NspHI) was developed and experimentally evaluated. Consistent with model predictions, the engi-neered strain exhibited lower growth rates and glucose uptake than the wild type, reflect-ing a metabolic burden. Nevertheless, 3,4-AHBA production was achieved exclusively in the engineered strain. Comparison of simulated and experimental fluxes revealed overes-timation by FBA, likely due to secondary metabolism and incomplete genome annotation. Overall, GSM-guided design enables optimization of precursor production.